Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$71.21 USD

71.21
1,484,211

-0.73 (-1.01%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $71.19 -0.02 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (170 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Masimo (MASI) Reports Preliminary Q1 Results, Reiterates '22 View

by Zacks Equity Research

Masimo's (MASI) first-quarter 2022 results are likely to have been dampened by supply chain headwinds.

Is Henry Schein (HSIC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Henry Schein (HSIC) and Humacyte, Inc. (HUMA) have performed compared to their sector so far this year.

Haemonetics' (HAE) Hospital Business Grows, Cost Ails Stay

by Zacks Equity Research

Haemonetics (HAE) has made the NexSys PCS devices available in the United States to ensure timely conversion of the remainder of its major customers to the same by mid-fiscal 2023.

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic's (HOLX) robust international performance and strength in its GYN Surgical business.

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

LHC Group's (LHCG) Deal With Optum to Boost Value-Based Care

by Zacks Equity Research

LHC Group's (LHCG) deal with Optum is likely to enhance and extend value-based care to patients' homes.

Here's Why You Should Retain Nevro (NVRO) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.

LabCorp (LH) Gains From Covance Arm Growth, Cost Pressure Ails

by Zacks Equity Research

LabCorp's (LH) Covance Drug Development arm is benefiting from its collaborations with leading pharmaceutical and biotechnology companies.

Veeva Systems (VEEV) Sees Wider Adoption of Its Development Cloud

by Zacks Equity Research

Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.

Henry Schein (HSIC) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Henry Schein (HSIC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here's Why You Should Retain STERIS (STE) Stock For Now

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) robust segmental performance and upbeat 2022 guidance.

Thermo Fisher (TMO) Launches NGS Platform for Clinical Labs

by Zacks Equity Research

Thermo Fisher's (TMO) Ion Torrent Genexus Dx Integrated Sequencer makes next-generation sequencing accessible for all clinical laboratories.

Reasons to Retain Ecolab (ECL) Stock in Your Portfolio For Now

by Zacks Equity Research

Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.

Here's Why You Should Hold on to Inogen (INGN) Stock Now

by Zacks Equity Research

Inogen (INGN) continues to benefit from strength in the direct-to-customer business model. However, rising costs remain a woe.

Here's Why You Should Hold on to NuVasive (NUVA) Stock for Now

by Zacks Equity Research

Investors are optimistic about NuVasive's (NUVA) better-than-expected revenues and strong spine market presence.

Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee and regulatory approvals.

Henry Schein (HSIC) Digital Dentistry Gains, Expands Globally

by Zacks Equity Research

Henry Schein (HSIC) witnesses strength in dental consumable merchandise sales in France, Germany, Austria, Belgium.

Masimo (MASI) Announces Favorable Study Results on SpHb

by Zacks Equity Research

Masimo's (MASI) SpHb is likely to enhance perioperative transfusion management and post-operative patient outcomes on pediatric patients.

Here's Why You Should Hold on to DexCom (DXCM) Stock Now

by Zacks Equity Research

DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.

Here's Why You Should Invest in IDEXX (IDXX) Stock for Now

by Zacks Equity Research

Investors are optimistic about IDEXX's (IDXX) strong international performances and favorable 2022 outlook.

Abbott's (ABT) CGM Device Gets MHLW Nod for Expanded Coverage

by Zacks Equity Research

Abbott's (ABT) FreeStyle Libre system will allow diabetics to get the glucose data required to manage their condition without using routine fingersticks.

Reasons to Retain Intuitive Surgical (ISRG) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Intuitive Surgical (ISRG) owing to its strength in robotics.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical's (GMED) better-than-expected results and strength in the U.S. Spine business.

Phibro (PAHC) Rises 6.1% Since Q2 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Phibro's (PAHC) booming vaccine business and strong global presence.

National Vision (EYE) Hurt by Rising Costs, Vendor Dependency

by Zacks Equity Research

High dependence on a limited number of suppliers exposes National Vision (EYE) to supplier concentration risk.